Reports Q4 revenue $11B, consensus $11.03B. “We finished the year with very strong momentum. Sales growth and earnings per share growth in the fourth quarter were the highest of the year,” said Robert B. Ford, chairman and chief executive officer, Abbott (ABT). “We continued our track record for delivering on our commitments by achieving the upper end of our initial guidance ranges for 2024 and are well-positioned to deliver another year of strong growth in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Notable companies reporting before tomorrow’s open
- Options Volatility and Implied Earnings Moves This Week, January 21 – January 24, 2025
- Abbott Laboratories (ABT) Q4 Earnings Cheat Sheet
- Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations
- Abbott price target lowered to $135 from $138 at Bernstein